Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 4/20 | 0.35 |
| ▸ | CES1 | P23141 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9267334 | 0.85 | FFAR3 (0.40) | FFAR3ALDH1A1TDP1TSHRCES2 | |
| SCHEMBL9268644 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL108375 | 0.73 | — | — | |
| SCHEMBL11654422 | 0.71 | ALDH1A1 (0.32) | FFAR3ALDH1A1TDP1TSHRSOAT1 | |
| SCHEMBL5902788 | 0.71 | CYP2C9 (0.35) | FFAR3ALDH1A1TDP1TSHR | |
| SCHEMBL9513753 | 0.71 | — | — | |
| SCHEMBL9513754 | 0.71 | — | — | |
| SCHEMBL811235 | 0.71 | — | — | |
| SCHEMBL811234 | 0.71 | — | — | |
| SCHEMBL11659065 | 0.69 | SOAT1 (0.35) | FFAR3ALDH1A1TDP1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890227-B1 | Compositions containing 1,1-di-substituted alkene compounds for preparing polymers having enhanced glass transition temperatures | SIRRUS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180037681-A1 | COMPOSITIONS CONTAINING 1,1-DI-SUBSTITUTED ALKENE COMPOUNDS FOR PREPARING POLYMERS HAVING ENHANCED GLASS TRANSITION TEMPERATURES | NIPPON SHOKUBAI CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-9790295-B2 | Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures | SIRRUS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160215078-A1 | COMPOSITIONS CONTAINING 1,1-DISUBSTITUTED ALKENE COMPOUNDS FOR PREPARING POLYMERS HAVING ENHANCED GLASS TRANSITION TEMPERATURES | SIRRUS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9315597-B2 | Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures | SIRRUS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160068621-A1 | COMPOSITIONS CONTAINING 1,1-DISUBSTITUTED ALKENE COMPOUNDS FOR PREPARING POLYMERS HAVING ENHANCED GLASS TRANSITION TEMPERATURES | NIPPON SHOKUBAI CO., LTD. (JP) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037681-A1 | COMPOSITIONS CONTAINING 1,1-DI-SUBSTITUTED ALKENE COMPOUNDS FOR PREPARING POLYMERS HAVING ENHANCED GLASS TRANSITION TEMPERATURES | GMNN, DAD1, MAGT1 | FFAR3 4242/4885ALDH1A1 1503/4885TDP1 74/4885 |
| US-20160215078-A1 | COMPOSITIONS CONTAINING 1,1-DISUBSTITUTED ALKENE COMPOUNDS FOR PREPARING POLYMERS HAVING ENHANCED GLASS TRANSITION TEMPERATURES | GMNN, PAG1, SMG1 | FFAR3 4344/4885ALDH1A1 1506/4885TDP1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.